Merck, Inc.
🇺🇸United States
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)
Phase 1
Completed
- Conditions
- Non-small Cell Lung Carcinoma
- Interventions
- Biological: PembrolizumabBiological: IpilimumabBiological: Bevacizumab
- First Posted Date
- 2014-01-17
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 267
- Registration Number
- NCT02039674
Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)
Phase 1
Completed
- Conditions
- Streptococcus Pneumoniae InfectionPneumococcal Infections
- Interventions
- Biological: Prevnar 13®
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 341
- Registration Number
- NCT02037984
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
Phase 1
Terminated
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT02036502
Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 464
- Registration Number
- NCT02036515
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Other: GlimepirideBiological: Basal Insulin
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 621
- Registration Number
- NCT02033889
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 382
- Registration Number
- NCT02028065
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: PlaceboBiological: Sandostatine®Biological: InsulinBiological: Glucagon
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02012166
Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 33
- Registration Number
- NCT02011490
- Locations
- 🇺🇸
Investigational Site 001, Hialeah, Florida, United States
Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT02007070
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 74
- Registration Number
- NCT02004886
© Copyright 2025. All Rights Reserved by MedPath